Third keystone symposium on cellular immunology and the immunotherapy of cancer tumor vaccines a reality at last?

Journal of Immunotherapy

Volumn 21, Issue 2, 1998, Pages 119-126

  Hellström, Ingegerd ^a   Hellström, Karl Erik ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTATION; CELLULAR IMMUNITY; CONFERENCE PAPER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TUMOR IMMUNOLOGY; VACCINATION;

ANIMALS; CANCER VACCINES; HISTORY, 20TH CENTURY; HUMANS; MICE;

EID: 0031952529     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199803000-00005     Document Type: Article

References (85)

1. Himmelweit B, ed. The collected papers of Paul Ehrlich. Oxford: Pergamon Press, 1957.
2. Coley W. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hosp 1896;7:157.
3. Old LJ, Boyse EA. Immunology of experimental tumors. Annu Rev Med 1964;15:167.
4. Baldwin RW. Immunological aspects of chemical carcinogenesis. Adv Cancer Res 1973;18:175.
5. Hellström KE, Hellström I. Tumor antigens recognized by monoclonal antibodies. In: DeVita VT, Heilman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: Lippincott, 1991:77.
6. Klein G, et al. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960:20:1561.
7. Sjögren HO, Hellström I, Klein G. Transplantation of polyoma virus-induced tumors in mice. Cancer Res 1961:21:329.
8. Habel K. Immunological determinants of polyoma virus oncogenesis. J Exp Med 1962:115:181.
9. Sjögren HO. Transplantation methods as a tool for detection of tumor specific antigens. Prog Exp Tumor Res 1965;6:289.
10. Mulé JJ, et al. Selective localization of radiolabelled immune lymphocytes into syngeneic tumors. J Immunol 1979:123:600.
11. Rosenberg S. Adoptive cellular therapy: clinical applications. In: DeVita VT, Heilman S, Rosenberg SA, eds. Biologic therapy of cancer: principles and practice. Philadelphia: Lippincott, 1991:214.
12. Hellström I. A colony inhibition (Cl) technique for demonstration of tumor cell destruction by lymphoid cells in vitro. Int J Cancer 1967:2:65.
13. Hellström I, Sjögren HO. In vitro demonstration of humoral and cell-bound immunity against common specific transplantation antigen(s) of adenovirus 12-induced mouse and hamster tumors. J Exp Med 1967:125:1105.
14. Hellström I, Hellström KE. In vitro demonstration of cell-bound immunity against autologous MCA and plastic disc-induced mouse tumors. Science 1967:156:981.
15. Gershom RK, Carter RL, Kondo K. Nature 1969:224:277.
16. Southam CM. Evidence for cancer-specific antigens in man. Prog Exp Tumor Res 1967;9:1.
17. Hellström K, Hellström I. Cellular immunity against tumor specific antigens. Adv Cancer Res 1969:12:167.
18. Hellström I, et al. Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci USA 1968;60:1231.
19. Hellström I, et al. Cellular and humoral immunity to different types of human neoplasms. Nature 1968:220:1352.
20. Hellström I, Evans CA, Hellstrom KE. Cellular immunity and its serum mediated inhibition in Shope virus-induced rabbit papillomas. Int J Cancer 1969;4:601.
21. Hellström K, Hellström I, Shepard TH. Cell-mediated immunity against antigens common to human colonic carcinomas and fetal gut epithelium. Int J Cancer 1970;6:346.
22. Hellström I, Hellström KE. Some recent studies on cellular immunity to human melanomas. Fed Proc 1973:32:156.
23. Wybran J, et al. Cytotoxicity of human rosette-forming lymphocytes on cultivated human tumor cells. Int J Cancer 1974;13:515.
24. Perlmann P, Cerottini JC. Cytotoxic lymphocytes. In: Sela M, ed. The antigens. New York: Academic Press, 1979.
25. Hewitt HB, Blake ER, Walder ES. A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 1976:33:241.
26. Prehn R. Immunostimulation of the lymphodependent phase of neoplastic growth. JNCI 1977;59:1043.
27. Herberman RB, Oldham RK. Problems associated with study of cell-mediated immunity to human tumor by microcytotoxicity assays. JNCI 1975:55:749.
28. Hellström I, Hellström KE. Cell-mediated reactivity to human tu-mor-type associated antigens: does it exist? J Biol Response Modif 1983;2:310.
29. Kohler G, Milstein G. Continuous culture of fused cells secreting antibodies of predefined specificity. Nature 1975;256:495.
30. Reisfeld R. Monoclonal antibodies in cancer immunotherapy. Clin Lab Med 1992;12:20.
31. Ferrone S, et al. Tumor antigens recognized by monoclonal antibodies. In: DeVita VT, Heilman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: Lippincott, 1991:77.
32. Hellström I, et al. Immunoconjugates and immunotoxins for therapy of carcinomas. Adv Pharmacol 1995;33:349.
33. Press O, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219.
34. Riethmüller G, et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 1994;343:1177.
35. Estin CD, et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA 1988;85:1052.
36. Tsang KY, et al. A recombinant CEA-vaccinia vaccine induces a CEA-specific cytotoxic T-cell response in carcinoma patients. Proc Am Assoc Cancer Res 1995;36:A1483.
37. Livingston PO, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036.
38. Herlyn D, Ross AH, Koprowski H. Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 1986;232:100.
39. Fagerberg J, et al. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995;92:4773.
40. Morton DL. Acquired immunological tolerance to spontaneous mammary adenocarcinomas following neonatal infection with mammary tumor agent (MTA). Proc Am Assoc Cancer Res 1964;5:A46.
41. Weiss DW, Faulkin LJ, DeOme KB. Acquisition of heightened resistance and susceptibility to spontaneous mouse mammary carcinomas in the original host. Cancer Res 1964;24:732.
42. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281.
43. Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58:143.
44. Boon T, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337.
45. Hellstrom KE, Hellstrom I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 1995;145:123.
46. Jagarlamoody SM, et al. In vitro detection of cytotoxic cellular immunity against tumor-specific antigens by a radioisotope technique. Proc Natl Acad Sci USA 1971;68:1346.
47. McCoy J, et al. Inhibition of leukocyte migration by tumorassociated antigens in soluble extracts of human malignant melanoma. JNCI 1975;59:1413.
48. Kadish AS, Marcus DM, Bloom BR. Inhibition of leukocyte migration by human breast cancer-associated antigens. Int J Cancer 1976;18:581.
49. Halliday W, et al. Cancer Res 1977;37:1962.
50. Cannon G, et al. Relationship of human natural lymphocytemediated cytotoxicity to cytotoxicity of breast-cancer-derived target cells. Int J Cancer 1977;19:487.
51. Steele G, Sjögren HO, Stadenberg I. In vitro cell-mediated immune reactions of melanoma in colorectal carcinoma patients demonstrated by long-term chromium assays. Int J Cancer 1976;17:27.
52. deVries JE, Rumke P. Tumour-associated lymphocyte cytotoxicity superimposed on “spontaneous” cytotoxicity in melanoma patients. Int J Cancer 1976;17:182.
53. deVries JE, Spitz H. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. In vitro generation, isolation, and analysis to phenotype and specificity. J Immunol 1984;132:510.
54. Mitchell MS, et al. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883.
55. Finn OJ, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61.
56. Van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643.
57. Storkus WJ, Lotze MT. Tumor antigens recognized by immune cells. In: DeVita VT, Heilman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: Lippincott, 1991.
58. Chen L, et al. Human papillomavirus type 16 nucleoprotein is a tumor rejection antigen. Proc Natl Acad Sci USA 1991;88:110.
59. Melief C, Kast W. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995;145:167.
60. Cheever M, et al. Immunity to oncogenic proteins. Immunol Rev 1995;145:33.
61. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 1996;93:15335.
62. Wolfel T, et al. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281.
63. Hellström KE, Hellström I. Oncogene-associated tumor antigens as targets for immunotherapy. FASEB J 1989;3:1715.
64. Marincola FM, et al. Loss of HLA haplotype and B locus downregulation in melanoma cell lines. J Immunol 1994;153:1225.
65. Maeurer MJ, et al. Tumor escape for immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-l/Melan-A antigen. J Clin Invest 1996;98:1633.
66. Garrido F, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997;18:89.
67. Restifo NP, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265.
68. Hellström I, Gladstone P, Hellström K. Cancer vaccines: challenges and potential solutions. Mol Med Today (in press).
69. Klein E, Klein G, Hellström KE. Further studies on isoantigenic variation in mouse carcinomas and sarcomas. JNCI 1960;25:271.
70. Porgador A, et al. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res 1995;55:4941.
71. Schwartz RH. Acquisition of immunological self-tolerance. Cell 1989;57:1073.
72. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191.
73. Lin H, et al. Review of CTLA41g use for allograft immunosuppression. Transplant Proc 1994;26:3200.
74. Chen L, et al. Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093.
75. Townsend SE, et al. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994;54:6477.
76. Li Y, et al. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996;183:639.
77. Melero I, et al. Anti 4-IBB monoclonal antibodies activate T cells and eradicate established tumors. Science (in press).
78. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994;180:211.
79. Hellström I, et al. Serum mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor specific antigens. Proc Natl Acad Sci USA 1969;62:362.
80. Hellström KE, Hellström I. Enhancement of tumor outgrowth by tumor-associated blocking factors. Int J Cancer 1979;23:366.
81. Mizoguchi H, et al. Alterations in signal transduction molecules in T-lymphocytes from tumor-bearing mice. Science 1992;258:1795.
82. Nakagomi H, et al. Decreased expression of the signal-transducing z chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610.
83. Snyderman R, Pike M. A macrophage chemotaxis inhibitor produced by neoplasms: characterization of its biological activity. Adv Exp Med Biol 1979;121:471.
84. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993;60:247.
85. Hahne M, et al. Melanoma cell expression of Fas (Apo-l/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363.